von Willebrand Factor
- 1 February 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 43 (2), 599-606
- https://doi.org/10.1161/strokeaha.111.628867
Abstract
Thrombus formation is of paramount importance in the pathophysiology of acute ischemic stroke. Current antithrombotics used to treat or prevent cerebral ischemia are only moderately effective or bear an increased risk of severe bleeding. von Willebrand factor (VWF) has long been known to be a key player in thrombus formation at sites of vascular damage. While the association between VWF and coronary heart disease has been well studied, knowledge about the role of VWF in stroke is much more limited. However, in recent years, an increasing amount of clinical and preclinical evidence has revealed the critical involvement of VWF in stroke development. This review summarizes the latest insights into the pathophysiologic role of VWF-related processes in ischemic brain injury under experimental conditions and in humans. Potential clinical merits of novel inhibitors of VWF-mediated platelet adhesion and activation as powerful and safe tools to combat thromboembolic disorders including ischemic stroke are discussed. Preclinical and clinical evidence illustrates an important role of VWF in ischemic stroke, suggesting that VWF could become a promising target in stroke therapy.Keywords
This publication has 88 references indexed in Scilit:
- Platelet glycoprotein Ibα is an important mediator of ischemic stroke in miceExperimental & Translational Stroke Medicine, 2011
- Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugsBlood, 2011
- von Willebrand factor–mediated platelet adhesion is critical for deep vein thrombosis in mouse modelsBlood, 2011
- Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular diseaseBlood, 2011
- von Willebrand factor–cleaving protease ADAMTS13 reduces ischemic brain injury in experimental strokeBlood, 2009
- Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled studyThe Lancet Neurology, 2009
- Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemiaThrombosis Research, 2008
- ADAMTS13: a new link between thrombosis and inflammationThe Journal of Experimental Medicine, 2008
- The vessel wall and its interactionsBlood, 2008
- von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veinsBlood, 2006